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Abstract 
Molecular alterations in KRAS, BRAF, PIK3CA, and PTEN have been implicated in 
designing targeted therapy for colorectal cancer (CRC). The present study aimed to determine 
the status of these molecular alterations in Malaysian CRCs as such data are not available in 
the literature. We investigated the mutations of KRAS, BRAF, and PTEN, the gene 
amplification of PIK3CA, and the protein expression of PTEN and phosphatidylinositol 3-
kinase (PI3K) catalytic subunit (p110α) by direct DNA sequencing, quantitative real-time 
PCR, and immunohistochemistry, respectively, in 49 CRC samples. The frequency of KRAS 
(codons 12, 13, and 61), BRAF (V600E), and PTEN mutations, and PIK3CA amplification 
was 25.0% (11/44), 2.3% (1/43), 0.0% (0/43), and 76.7% (33/43), respectively. 
Immunohistochemical staining demonstrated loss of PTEN protein in 54.5% (24/44) of CRCs 
and no significant difference in PI3K p110α expression between CRCs and the adjacent 
normal colonic mucosa (p = 0.380). PIK3CA amplification was not associated with PI3K 
p110α expression level, but associated with male cases (100% of male cases vs 56% of 
female cases harbored amplified PIK3CA, p = 0.002). PI3K p110α expression was 
significantly higher (p = 0.041) in poorly/moderately differentiated carcinoma compared with 
well-differentiated carcinoma. KRAS mutation, PIK3CA amplification, PTEN loss, and PI3K 
p110α expression did not correlate with Akt phosphorylation or Ki-67 expression. KRAS 
mutation, PIK3CA amplification, and PTEN loss were not mutually exclusive. This is the 
first report on CRC in Malaysia showing comparable frequency of KRAS mutation and 
PTEN loss, lower BRAF mutation rate, higher PIK3CA amplification frequency, and rare 
PTEN mutation, as compared with published reports. 
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